| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 12/06/2001 | WO2001092542A2 Integrin-targeting vectors having enhanced transfection activity |
| 12/06/2001 | WO2001092528A2 Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 12/06/2001 | WO2001092527A2 Regulators of apoptosis |
| 12/06/2001 | WO2001092526A1 Human kcnq5 potassium channel, methods and compositions thereof |
| 12/06/2001 | WO2001092525A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 12/06/2001 | WO2001092522A2 Human fgf-20 nucleic acids and polypeptides |
| 12/06/2001 | WO2001092513A1 METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi |
| 12/06/2001 | WO2001092507A1 Shedding fragments of cd44, utilization thereof and inhibition of the shedding |
| 12/06/2001 | WO2001092496A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 12/06/2001 | WO2001092492A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 12/06/2001 | WO2001092491A2 Mammalian protein phosphatases identified by in-silico analysis |
| 12/06/2001 | WO2001092490A2 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 12/06/2001 | WO2001092484A2 Adjuvant preparation for the induction of specific immunity |
| 12/06/2001 | WO2001092474A1 Alpha (2) macroglobulin receptors as a heat shock protein receptor and uses thereof |
| 12/06/2001 | WO2001092333A2 Use of adnf for enhancing learning and memory |
| 12/06/2001 | WO2001092308A2 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 12/06/2001 | WO2001092307A2 Therapeutic compounds for ovarian cancer |
| 12/06/2001 | WO2001092306A2 Therapeutic compounds for ovarian cancer |
| 12/06/2001 | WO2001092304A2 Transporters and ion channels |
| 12/06/2001 | WO2001092299A2 Adenovirus particles with mutagenized fiber proteins |
| 12/06/2001 | WO2001092295A2 Ligands for cd21 and compositions thereof for modulating immune responses |
| 12/06/2001 | WO2001092294A2 Therapeutic anti-melanoma compounds |
| 12/06/2001 | WO2001092262A1 New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound |
| 12/06/2001 | WO2001092253A2 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 12/06/2001 | WO2001092245A1 Novel paclitaxel derivatives for the treatment of cancer |
| 12/06/2001 | WO2001092244A1 Inhibitors of matrix metalloproteinases |
| 12/06/2001 | WO2001092224A1 Indole derivatives with vascular damaging activity |
| 12/06/2001 | WO2001092221A1 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds |
| 12/06/2001 | WO2001092220A1 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof |
| 12/06/2001 | WO2001092218A2 Polyamine analogues as therapeutic and diagnostic agents |
| 12/06/2001 | WO2001092210A1 Compounds for modulating the rage receptor |
| 12/06/2001 | WO2001091808A2 Bioconjugates of nanoparticles as radiopharmaceuticals |
| 12/06/2001 | WO2001091805A2 Compounds for targeting endothelial cells |
| 12/06/2001 | WO2001091803A2 Methods and compounds for controlled release of recombinant parvovirus vectors |
| 12/06/2001 | WO2001091800A1 Ubiquitin promoter in vectors for gene therapy in respiratory tract |
| 12/06/2001 | WO2001091794A2 Vitamin d3 analogs as radiosensitizers for the treatment of cancer |
| 12/06/2001 | WO2001091793A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 12/06/2001 | WO2001091792A2 Anti-adhesion molecule antibody to treat inflammation and cancer by inducing the idiotypic network |
| 12/06/2001 | WO2001091791A2 Immune-stimulating bacterial cell wall extracts |
| 12/06/2001 | WO2001091789A2 Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
| 12/06/2001 | WO2001091787A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | WO2001091781A2 Thrombospondin type 1 repeat polypeptides |
| 12/06/2001 | WO2001091780A1 Neuroprotective peptides |
| 12/06/2001 | WO2001091763A2 Extracts from spermatophyte plants with antitumor activity |
| 12/06/2001 | WO2001091754A1 Protein kinase inhibitors |
| 12/06/2001 | WO2001091742A1 Pharmaceutical composition containing at least a polymer associated or conjugated with at least a phenylalkylcarboxylic acid salt, conjugate polymers and uses thereof |
| 12/06/2001 | WO2001091740A2 Compositions containing naphthaquinone and an antiproliferative agent |
| 12/06/2001 | WO2001091739A2 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
| 12/06/2001 | WO2001091735A2 Use of aloe-emodin in the treatment of neuroectodermal tumors |
| 12/06/2001 | WO2001091729A1 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base |
| 12/06/2001 | WO2001091699A2 Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways |
| 12/06/2001 | WO2001062760A3 A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR |
| 12/06/2001 | WO2001053351A3 Apoptin bindendes protein |
| 12/06/2001 | WO2001049717A3 Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or t cell subset activity by modulation of xbp-1 activity |
| 12/06/2001 | WO2001049673A3 Compounds and methods for modulation of estrogen receptors |
| 12/06/2001 | WO2001047546A3 Methods and products for tumor immunotherapy using cytokines |
| 12/06/2001 | WO2001046392A3 Homologues of human heparanase and splice variants thereof |
| 12/06/2001 | WO2001046178A3 Substituierte bisindolymaleimide |
| 12/06/2001 | WO2001034201A3 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 12/06/2001 | WO2001034130A9 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 12/06/2001 | WO2001030854A3 Antibody to human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin |
| 12/06/2001 | WO2001030381A3 Use of csf-1 inhibitors |
| 12/06/2001 | WO2001023421B1 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| 12/06/2001 | WO2001023362A3 Rate-controlled particles |
| 12/06/2001 | WO2001022922A3 Engineering antibodies that bind irreversibly |
| 12/06/2001 | WO2001019800A3 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 12/06/2001 | WO2001018042A3 Apoptosis proteins |
| 12/06/2001 | WO2001012775A8 25 human secreted proteins |
| 12/06/2001 | WO2001012662A3 Membrane associated proteins |
| 12/06/2001 | WO2001010847A8 Novel integrin receptor antagonists |
| 12/06/2001 | WO2000077206A3 The myostatin gene promoter and inhibition of activation thereof |
| 12/06/2001 | WO2000062808A8 Cobalamin conjugates useful as antitumor agents |
| 12/06/2001 | WO2000061750A3 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS |
| 12/06/2001 | WO2000011166A9 14274 receptor, a g-protein coupled receptor related to the edg receptor family |
| 12/06/2001 | US20010049449 Aromatic sulfonyl alpha-cycloamino hydroxamates and their use as MMP inhibitors |
| 12/06/2001 | US20010049446 C-C9-Heteroaryl, linked via C or N, substituted or unsubstitued by 1,3-substituents, substituted benzoylguanidine derivatives useful for treating ischemia, cardiac infarct, angina pectoris, and storke etc. |
| 12/06/2001 | US20010049435 Myostatin gene promoter and inhibition of activation thereof |
| 12/06/2001 | US20010049387 Use in the treatment of cancer, as tubulin polymerizers and as microtubule stabilization agents. |
| 12/06/2001 | US20010049376 Method of prevention of prostatic carcinoma with 17beta-N-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones |
| 12/06/2001 | US20010049371 Reducing levels of tumor necrosis factor alpha; inhibition of undesireable levels of matrix metalloproteinases |
| 12/06/2001 | US20010049364 Prevention of cancer |
| 12/06/2001 | US20010049360 Betaglycan as an inhibin receptor and uses thereof |
| 12/06/2001 | US20010049355 Providing exogenous SLED to endothelial cells; maybe be provided systemically, topically, or via a vector comprising a SLED expression cassette |
| 12/06/2001 | US20010049350 Adjusting the prolactin and melatonin profiles of the mammal by administering prolactin enhancers or reducers and melatonin so that the prolactin and melatonin profiles conform to or approach normal profiles |
| 12/06/2001 | US20010049349 Antioxidant enhancement of therapy for hyperproliferative conditions |
| 12/06/2001 | US20010049142 A rapid, simple-to-use method to differentiate nondividing cells by fusing two different cells and then purifying them without antibiotic or metabolic selection; kits with two nontoxic dyes and instructions; antitumor agents |
| 12/06/2001 | US20010049122 For reducing inflammation, for treating an autoimmune disease, for enhancing transplantation of tissue grafts, increasing antitumor immunity, and inhibiting viral and parasitic infections |
| 12/06/2001 | US20010049106 ADAM (A Disintegrin And Metalloprotease) family of metalloproteases, and in addition contain thrombospondin domain (TS); treating diabetes, arthritis, cancer, solid tumors, autoimmune diseases |
| 12/06/2001 | US20010048921 Forming chimeric bone marrow |
| 12/06/2001 | US20010048920 Reovirus for the treatment of neoplasia |
| 12/06/2001 | US20010048914 Radioactive therapeutic liposomes |
| 12/06/2001 | DE10026699A1 Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage Formulation of heparin, glycosaminoglycan or Heparinoidbasis and use of the formulation and the formulation base |
| 12/06/2001 | DE10025464A1 Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen Combined use of enzyme inhibitors for the therapy of autoimmune diseases, transplantation and tumor diseases as well as combinations of enzyme inhibitors pharmaceutical preparations comprising |
| 12/06/2001 | CA2599562A1 Compounds for modulating the rage receptor |
| 12/06/2001 | CA2414207A1 Adjuvant preparation for the induction of specific immunity |
| 12/06/2001 | CA2411655A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 12/06/2001 | CA2411404A1 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 12/06/2001 | CA2411040A1 Therapeutic anti-melanoma compounds |
| 12/06/2001 | CA2410981A1 Adenovirus particles with mutagenized fiber proteins |
| 12/06/2001 | CA2410947A1 Methods for mediating gene suppresion by using factors that enhance rnai |